Organon Pharma Indonesia Tbk. vs Hatten Bali Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Hatten Bali Tbk. trades at Rp129 (market cap 357.72B, 823.4K 24h volume). The key difference: Hatten Bali Tbk. is far larger — about 3.4× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | WINE | |
|---|---|---|
Market Cap | 104.4B | 357.72B |
Volume | — | 823.4K |
Lot | — | 8.23K |
Turnover | — | 106.82M |
Average Price | — | 129.73 |
Value | — | 106.82M |
Indicative Equilibrium Price | — | 129 |
Indicative Equilibrium Volume | — | 2 |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT Hatten bali, Tbk. (the Company) was established in Bali based on the Notarial Deed No. 90, dated April 15, 2000, drawn up before, I Putu Chandra, S.H Notary at Denpasar. The Company started its commercial operations in 2003.
Read more on WINE →